Credentials
Positions
- Assistant Professor, Department of Medicine at NYU Grossman School of Medicine
Board Certifications
- American Board of Internal Medicine (Critical Care Medicine), 2012
- American Board of Internal Medicine (Pulmonary Disease), 2011
- American Board of Internal Medicine - Internal Medicine, 2009
Education and Training
- Fellowship, NYU School of Medicine, Pulm & Critical Care, 2012
- Residency, NYU School of Medicine, Internal Medicine, 2009
- MD from Technical University of Munich, 2003
Is this your profile?
Edit profileInsurance Plans Accepted
This provider accepts the following insurance plans.
-
Aetna
- Aetna HMO
- Aetna Indemnity
- Aetna Medicare
- Aetna POS
- Aetna PPO/EPO
-
Agewell
- Agewell
-
Cigna
- Cigna EPO/POS
- Cigna PPO
-
ElderPlan
- ElderPlan
-
Emblem
- Emblem Select Care Exchange
-
Empire Blue Cross Blue Shield
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield HealthPlus
- Empire Blue Cross Blue Shield HealthPlus Essential
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield MediBlue
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
-
GHI
- GHI CBP
- GHI HMO
-
HIP
- HIP Access I
- HIP Access II
- HIP Child Health
- HIP EPO/PPO
- HIP Essential
- HIP HMO
- HIP Medicaid
- HIP Medicare
- HIP POS
-
HealthSmart
- HealthSmart (WTC)
-
Healthfirst
- Healthfirst
- Healthfirst Essential
-
Hotel Trades
- Hotel Trades
-
Humana
- Humana Medicare
-
Local 1199
- Local 1199 PPO
-
MagnaCare
- MagnaCare PPO
-
Medicaid
- NY Medicaid
-
Medicare
- Medicare
-
MetroPlus
- MetroPlus Child Health
- MetroPlus Essential
- MetroPlus Exchange Plans
- MetroPlus Medicaid
- MetroPlus Medicare
-
MultiPlan/PHCS
- MultiPlan/PHCS PPO
-
NYS Health Insurance Plan
- The Empire Plan
-
Oxford
- Oxford Freedom
- Oxford Liberty
- Oxford Medicare
-
PHP
- PHP
-
Railroad Medicare
- Railroad Medicare
-
Tricare
- Tricare
-
UHC
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare Medicare
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
-
UPN
- UPN Elite
-
VNS
- Visiting Nurse Service (VNS) Medicare
-
Village Caremax
- Village Caremax
Locations and Appointments
NYU Langone Orthopedic Pulmonary Associates
301 East 17th Street, Suite 550
New York, NY 10003
NYU Critical Care Associates
550 1st Avenue
New York, NY 10016
Research My Research
Interests
adult fibrosing lung diseases, idiopathic pulmonary fibrosis, IPF
Research Summary
Two areas of interest evolved from my research and clinical activities. On the cell biology level, I am interested in how cell surface receptors communicate with their environment in physiologic and pathophysiologic states. The functional consequences of altered signaling are of particular interest for me as a physician since they give me further insight into disease mechanisms, such as aberrant integrin or growth factor receptor signaling in pulmonary fibrosis. On the clinical level, I have become particularly interested in IPF (idiopathic pulmonary fibrosis), a fatal, progressive lung disease with unpredictable clinical course, a median survival of <4 years and no effective treatment. Despite extensive research its underlying mechanisms remain unclear. One potential way I have studied involves EMT. In EMT, epithelial cell injury induces phenotype change to a mesenchymal type, resulting in interstitial matrix accumulation in alveolar walls and progressive pulmonary fibrosis with loss of function. Another potential mechanism I am currently studying involves embryonic signaling pathways, such as Hedgehog (HH) signaling, which are usually suppressed in adult uninjured lung, but might become reactivated as pathogenic mechanism in IPF.
In our lab we have shown HH pathway reactivation in lung fibroblasts in two important settings: (1) during alveolar septum formation in the postnatal lung and (2) in bleomycin-injured fibrotic lung. In the early postnatal developmental setting, inhibition of HH signaling produced alveolar airspace enlargement and septum wall thinning without affecting septum formation. This indicates the importance of precise temporal decrease in mesenchyme for normal lung structure. In the pathophysiological setting, the exacerbation of bleomycin-induced fibrosis by SHH over-expression implies that aberrant pathway activity prevents the demise of lung fibroblasts during fibrosis resolution.
The long-term goals of my work are to better understand the molecular signatures of pulmonary fibrosis by studying their characteristics in pathophysiologically relevant mouse models to elucidate novel mechanisms and improve treatment options.
Research Interests Timeline
Publications
-
Brosnahan, Shari B; Jonkman, Annemijn H; Kugler, Matthias C; Munger, John S; Kaufman, David A
Arteriosclerosis, thrombosis, & vascular biology. 2020 Sep 22; ATVBAHA120314515
-
Boytard, Ludovic; Hadi, Tarik; Silvestro, Michele; Qu, Hengdong; Kumpfbeck, Andrew; Sleiman, Rayan; Fils, Kissinger Hyppolite; Alebrahim, Dornazsadat; Boccalatte, Francesco; Kugler, Matthias; Corsica, Annanina; Gelb, Bruce E; Jacobowitz, Glenn; Miller, George; Bellini, Chiara; Oakes, Jessica; Silvestre, Jean-Sébastien; Zangi, Lior; Ramkhelawon, Bhama
Nature communications. 2020 Aug 27; 11(1):4311
-
Gibson, Charlisa D; Kugler, Matthias C; Deshwal, Himanshu; Munger, John S; Condos, Rany
Lung. 2020 Aug ; 198(4):597-608